You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma
|
---|---|
Published in |
Journal for Immunotherapy of Cancer, November 2013
|
DOI | 10.1186/2051-1426-1-s1-p84 |
Authors |
Igor Puzanov, Mohammed Milhem, Robert Andtbacka, David Minor, Omid Hamid, Ai Li, Ari VanderWalde, Howard Kaufman |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 32 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 4 | 13% |
Student > Bachelor | 2 | 6% |
Professor | 2 | 6% |
Student > Doctoral Student | 1 | 3% |
Student > Master | 1 | 3% |
Other | 1 | 3% |
Unknown | 21 | 66% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 22% |
Agricultural and Biological Sciences | 3 | 9% |
Biochemistry, Genetics and Molecular Biology | 1 | 3% |
Unknown | 21 | 66% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 February 2019.
All research outputs
#7,355,930
of 25,374,647 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,808
of 3,421 outputs
Outputs of similar age
#64,633
of 228,798 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#24
of 62 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,798 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.